KR101671452B1 - 항ｒｓｖ ｇ 단백질 항체 - Google Patents

항ｒｓｖ ｇ 단백질 항체 Download PDF

Info

Publication number
KR101671452B1
KR101671452B1 KR1020107011433A KR20107011433A KR101671452B1 KR 101671452 B1 KR101671452 B1 KR 101671452B1 KR 1020107011433 A KR1020107011433 A KR 1020107011433A KR 20107011433 A KR20107011433 A KR 20107011433A KR 101671452 B1 KR101671452 B1 KR 101671452B1
Authority
KR
South Korea
Prior art keywords
seq
ser
positions
region consisting
thr
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020107011433A
Other languages
English (en)
Korean (ko)
Other versions
KR20100091195A (ko
Inventor
로렌스 엠. 카우바
엘렌 제이. 콜라리니
브루스 키이트
오리트 푸어드
Original Assignee
트렐리스 바이오싸이언스 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 트렐리스 바이오싸이언스 인코포레이티드 filed Critical 트렐리스 바이오싸이언스 인코포레이티드
Publication of KR20100091195A publication Critical patent/KR20100091195A/ko
Application granted granted Critical
Publication of KR101671452B1 publication Critical patent/KR101671452B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1027—Paramyxoviridae, e.g. respiratory syncytial virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/54—F(ab')2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/11011—Alpharetrovirus, e.g. avian leucosis virus

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Pulmonology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Breeding Of Plants And Reproduction By Means Of Culturing (AREA)
KR1020107011433A 2007-10-25 2008-10-24 항ｒｓｖ ｇ 단백질 항체 Active KR101671452B1 (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US46907P 2007-10-25 2007-10-25
US61/000,469 2007-10-25
US8940108P 2008-08-15 2008-08-15
US61/089,401 2008-08-15
PCT/US2008/081175 WO2009055711A2 (en) 2007-10-25 2008-10-24 Anti-rsv g protein antibodies

Publications (2)

Publication Number Publication Date
KR20100091195A KR20100091195A (ko) 2010-08-18
KR101671452B1 true KR101671452B1 (ko) 2016-11-17

Family

ID=40580419

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020107011433A Active KR101671452B1 (ko) 2007-10-25 2008-10-24 항ｒｓｖ ｇ 단백질 항체

Country Status (14)

Country Link
US (3) US7736648B2 (enExample)
EP (1) EP2214711B1 (enExample)
JP (2) JP5808536B2 (enExample)
KR (1) KR101671452B1 (enExample)
CN (1) CN101808663B (enExample)
AU (1) AU2008316703B2 (enExample)
BR (1) BRPI0819210A2 (enExample)
CA (1) CA2703667C (enExample)
IL (1) IL205257A (enExample)
MX (1) MX2010004482A (enExample)
NZ (1) NZ585589A (enExample)
RU (1) RU2526517C2 (enExample)
WO (1) WO2009055711A2 (enExample)
ZA (1) ZA201003131B (enExample)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2506746A1 (en) * 2002-11-26 2004-06-10 Gilead Sciences, Inc. Method of drug loading in liposomes by gradient
CN101808663B (zh) * 2007-10-25 2015-09-30 特雷利斯生物科学股份有限公司 抗rsv g蛋白抗体
WO2013095091A2 (en) 2011-11-17 2013-06-27 Aimm Therapeutics B.V. Rsv g protein specific antibodies
US9475872B2 (en) * 2011-12-28 2016-10-25 Immunoqure Ag Nucleic acid molecules encoding moonoclonal antibodies speceific for IL17F
US10131709B2 (en) 2011-12-28 2018-11-20 Immunoqure Ag Nucleic acid molecules encoding monoclonal antibodies specific for IL-22
WO2013119419A1 (en) 2012-02-08 2013-08-15 North Carolina State University Treatment of allergic diseases with recombinant antibodies
TWI659968B (zh) 2013-03-14 2019-05-21 再生元醫藥公司 針對呼吸道融合病毒ｆ蛋白質的人類抗體及其使用方法
CN111303278B (zh) * 2013-04-15 2022-09-06 扬森疫苗与预防公司 结合到rsv g蛋白的人类抗体
AU2014255865B2 (en) * 2013-04-15 2019-07-18 Janssen Vaccines & Prevention B.V. Human antibodies binding to RSV G proteins
KR102201554B1 (ko) * 2013-04-15 2021-01-12 얀센 백신스 앤드 프리벤션 비.브이. Ｒｓｖ ｇ 단백질에 결합하는 인간 항체
DK3105250T3 (da) * 2014-02-10 2020-09-28 Igm Biosciences Inc Multispecifikke iga-bindingsmolekyler
CN103911389A (zh) * 2014-04-09 2014-07-09 南昌大学 一种检测人呼吸道合胞病毒抗体的g和f蛋白的制备方法
CN113429484A (zh) 2014-12-05 2021-09-24 纪念斯隆-凯特琳癌症中心 靶向g-蛋白偶联受体的抗体和使用方法
CN113683711A (zh) 2014-12-05 2021-11-23 纪念斯隆-凯特琳癌症中心 靶向g-蛋白偶联受体的嵌合抗原受体及其用途
CN106496324B (zh) 2015-11-30 2020-01-14 天津昊免生物技术有限公司 一种抗呼吸道合胞病毒的全人源抗体
CN109232737A (zh) * 2016-03-01 2019-01-18 苏州博泰神州生物技术有限公司 一种针对rsv粘附g蛋白表面抗原的全人源单克隆抗体
JP7127859B2 (ja) 2016-11-09 2022-08-30 ノース カロライナ ステート ユニバーシティ キメラタンパク質を用いたアレルギー疾患の治療
US10995145B2 (en) 2017-01-27 2021-05-04 Ngm Biopharmaceuticals, Inc. Antibodies which bind human glucagon receptor
WO2019075400A1 (en) * 2017-10-13 2019-04-18 Trellis Bioscience, Llc CONFORMATIONAL EPITOPES IN A CENTRAL PROTECTED REGION OF SYNCYTIAL RESPIRATORY VIRUS PROTEIN G
WO2019183437A1 (en) 2018-03-23 2019-09-26 North Carolina State University Methods and compositions for antibody to high affinity receptor for ige
WO2020023847A1 (en) 2018-07-27 2020-01-30 Ngm Biopharmaceuticals, Inc. Use of glucagon receptor antagonists with immunotherapeutic agent
WO2020033742A1 (en) * 2018-08-08 2020-02-13 Trellis Bioscience, Llc Improved rsv passive and active vaccines
AU2020227545B2 (en) 2019-02-28 2023-10-19 Km Biologics Co., Ltd. RSV F/G chimeric vaccine
WO2021046413A1 (en) 2019-09-06 2021-03-11 Silgan White Cap LLC Tethered, hinged closure
US20220362371A1 (en) * 2019-09-20 2022-11-17 Universiteit Antwerpen Human respiratory syncytial virus strain and its use
EP4429966A1 (en) 2021-11-08 2024-09-18 Silgan White Cap LLC Protrusion on container neck
WO2024027708A1 (zh) * 2022-08-02 2024-02-08 诺纳生物（苏州）有限公司 Msln抗体药物偶联物
WO2025106427A1 (en) * 2023-11-14 2025-05-22 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Neutralizing and protective monoclonal antibodies against respiratory syncytial virus (rsv)
WO2025194126A1 (en) * 2024-03-15 2025-09-18 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Respiratory syncytial virus (rsv) g and f antibodies with high rsv-neutralizing potency

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007101441A1 (en) * 2006-03-06 2007-09-13 Symphogen A/S Recombinant polyclonal antibody for treatment of respiratory syncytial virus infections

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE196737T1 (de) * 1993-05-25 2000-10-15 American Cyanamid Co Adjuvantien für impfstoffe gegen das respiratorische synzitialvirus
US6020182A (en) * 1996-07-12 2000-02-01 Connaught Laboratories Limited Subunit respiratory syncytial virus vaccine preparation
FR2766192B1 (fr) * 1997-07-17 2001-07-13 Pf Medicament Epitopes du vrs et anticorps les comportant, utiles dans le diagnostic et la therapie
US6642062B2 (en) 1998-09-03 2003-11-04 Trellis Bioinformatics, Inc. Multihued labels
US7083950B2 (en) 1998-09-25 2006-08-01 Regeneron Pharmaceuticals, Inc. High affinity fusion proteins and therapeutic and diagnostic methods for use
AU770737B2 (en) 1999-01-22 2004-03-04 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Methods for the prevention and treatment of diseases caused by an inflammatory response mediated by endogenous substance P by using anti-substance P antibodies
ATE412666T1 (de) 2000-10-18 2008-11-15 Us Gov Health & Human Serv Zusammensetzungen und verfahren zur modulierung von rsv-infektionen und -immunität
US7413868B2 (en) 2003-11-05 2008-08-19 Trellis Bioscience, Inc. Use of particulate labels in bioanalyte detection methods
JP4736037B2 (ja) * 2005-10-26 2011-07-27 株式会社イーベック ヒトｇｍ−ｃｓｆに結合するヒトのモノクローナル抗体並びにその抗原結合部分
CN1986569A (zh) * 2005-12-23 2007-06-27 首都儿科研究所 人源抗呼吸道合胞病毒中和性基因工程Fab抗体
JPWO2007094423A1 (ja) * 2006-02-15 2009-07-09 株式会社イーベック ヒトサイトメガロウイルスに結合するヒトのモノクローナル抗体並びにその抗原結合部分
WO2008008858A2 (en) 2006-07-12 2008-01-17 Trellis Bioscience, Inc. Cellspot™ applications
CN101808663B (zh) * 2007-10-25 2015-09-30 特雷利斯生物科学股份有限公司 抗rsv g蛋白抗体

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007101441A1 (en) * 2006-03-06 2007-09-13 Symphogen A/S Recombinant polyclonal antibody for treatment of respiratory syncytial virus infections

Also Published As

Publication number Publication date
CA2703667A1 (en) 2009-04-30
EP2214711A2 (en) 2010-08-11
IL205257A0 (en) 2010-12-30
RU2010120879A (ru) 2011-11-27
WO2009055711A2 (en) 2009-04-30
US7736648B2 (en) 2010-06-15
AU2008316703A2 (en) 2010-07-22
RU2526517C2 (ru) 2014-08-20
ZA201003131B (en) 2011-03-30
WO2009055711A3 (en) 2009-09-24
NZ585589A (en) 2012-07-27
MX2010004482A (es) 2010-07-06
EP2214711A4 (en) 2011-12-21
BRPI0819210A2 (pt) 2015-06-23
US20100285022A1 (en) 2010-11-11
US20130034564A1 (en) 2013-02-07
US20090130120A1 (en) 2009-05-21
AU2008316703B2 (en) 2012-09-27
CN101808663B (zh) 2015-09-30
CA2703667C (en) 2015-12-29
CN101808663A (zh) 2010-08-18
US8273354B2 (en) 2012-09-25
IL205257A (en) 2014-12-31
KR20100091195A (ko) 2010-08-18
US9321830B2 (en) 2016-04-26
JP2015078231A (ja) 2015-04-23
AU2008316703A1 (en) 2009-04-30
JP5808536B2 (ja) 2015-11-10
EP2214711B1 (en) 2018-08-15
JP2011500091A (ja) 2011-01-06

Similar Documents

Publication Publication Date Title
KR101671452B1 (ko) 항ｒｓｖ ｇ 단백질 항체
EP2289550A2 (en) Ultra high affinity neutralizing antibodies
US20230174628A1 (en) Anti-novel coronavirus monoclonal antibody and application thereof
US20240336672A1 (en) Human neutralizing monoclonal antibodies against sars-cov-2 and uses thereof
RS50157B (sr) Neutrališuća visoko afinitivna humana monoklonalna antitela specifična za rsv f-protein i postupci za njihovu proizvodnju
CN116785427B (zh) 呼吸道合胞病毒特异性结合分子的用途
EA035846B1 (ru) Антитела человека, связывающиеся с g-белком rsv
KR20090088871A (ko) 인간 메타뉴모바이러스를 중화시키는 인간 항체
US9017668B2 (en) High affinity human antibodies to human cytomegalovirus (CMV) gB protein
WO2017027805A1 (en) Human antibodies against rabies and uses thereof
TW202306980A (zh) 一種呼吸道融合病毒的抗體及其應用
CN114174331A (zh) 结合人类偏肺病毒融合蛋白的抗体及其用途
KR20150135231A (ko) 인간 메타뉴모바이러스에 특이적인 인간 항체 또는 그의 항원 결합성 단편
EP4442276A1 (en) Combined antibodies against sarbecoviruses and uses thereof
US20220340658A1 (en) NEUTRALIZING ANTI-SARS-CoV-2 ANTIBODIES AND USE THEREOF
WO2023094980A1 (en) Antibodies to coronavirus
CN104628850B (zh) Rsv-特异性结合分子
WO2025022303A1 (en) Antibodies against covid-19 and other human coronaviruses
AU2006203015B2 (en) Ultra high affinity neutralizing antibodies
AU2012213962A1 (en) Ultra high affinity neutralizing antibodies
HK1154803A (en) Ultra high affinity neutralizing antibodies

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20100525

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20131024

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20150421

Patent event code: PE09021S01D

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20151126

Patent event code: PE09021S01D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20160727

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20161026

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20161027

End annual number: 3

Start annual number: 1

PG1601 Publication of registration
PR1001 Payment of annual fee

Payment date: 20220915

Start annual number: 7

End annual number: 7

PR1001 Payment of annual fee

Payment date: 20230918

Start annual number: 8

End annual number: 8

PR1001 Payment of annual fee

Payment date: 20240919

Start annual number: 9

End annual number: 9